Unmet needs related to quality of life: Questionnaire-based survey in a breast cancer patient follow-up program

2015 ◽  
Vol 41 (1) ◽  
pp. S3
Author(s):  
S.D. Soysal ◽  
A. Posabella ◽  
S. Muenst ◽  
C.T. Viehl ◽  
A. Imgraben ◽  
...  
2021 ◽  
Author(s):  
BERNA KURT ◽  
ZEYNEP SİPAHİ KARSLI ◽  
BERNA ÖMÜR ÇAKMAK ÖKSÜZOĞLU ◽  
EMİNE ÖZTÜRK ◽  
NESLİHAN DEMİRÖRS ◽  
...  

Abstract Background The objective of this study is to evaluate the impact of peripheral neuropathy on the quality of life of breast cancer patients throughout with monthly follow-up during 4 months of paclitaxel treatment.Material and methods The research was conducted with a prospective cross sectional with four follow-ups descriptive design. The study population consisted of female patients with breast cancer at Ankara Oncology Training and Research Hospital between August 2018 and January 2019. Data were collected the ‘’Patient Information Form’’,‘’EORTC C30 Cancer Quality Of Life Questionnaire’’ and ‘’Chemotherapy-Induced Peripheral Neuropathy Assessment Tool’’. The study was undertaken in accordance with the STROBE checklist for cross-sectional studies. Results Of 79 patients included in the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool except for the general activity subdimension were statistically significant in the ratings of 2nd, compared to 1st; 3rd compared to 1st and 2nd; 4th compared to 1st, 2nd, and 3rd follow-up periods. The overall mean of EORTC C30 Cancer Quality of Life Questionnaire, functional subdimension, symptom severity, and general well-being in the evaluations of 2nd, compared with 1st; 3rd compared with 1st and 2nd; 4th compared with 1st, 2nd, and 3rd follow-up periods it was found that the mean values of symptom that decreased gradually were statistically significant.Conclusion The neuropathy scale was found to be higher in 2nd, 3rd, 4th follow-up periods than in 1st follow-up. Also, EORTC C30 Cancer QLQ subdimensions were high initially but gradually decreased after the fourth cycle. Thus, it was found that the increase in neuropathy symptoms negatively affects the quality of life.


2020 ◽  
Vol 66 (1) ◽  
Author(s):  
Monique Binotto ◽  
Gilberto Schwartsmann

Introdução: O câncer de mama pode alterar a qualidade de vida relacionada à saúde das pacientes. Objetivo: Compreender o impacto da quimioterapia para câncer de mama na qualidade de vida relacionada à saúde de pacientes. Método: Trata-se de uma revisão integrativa da literatura, compreendendo artigos publicados entre 2007 e 2019, disponíveis nas bases de dados PubMed, LILACS e SciELO. Analisaram-se 25 artigos na íntegra. Resultados: Os questionários mais frequentemente utilizados nos estudos foram o European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) e o módulo complementar European Organization for Research and Treatment of Cancer Breast Cancer-specific Quality of Life Questionnaire (EORTC QLQ-BR23). Em relação às alterações da qualidade de vida, a saúde global diminui durante a quimioterapia, mas pode melhorar após o término do tratamento. O aumento dos sintomas é relatado em diversos estudos e prejudicou a qualidade de vida relacionada à saúde das pacientes. Entretanto, os sintomas diminuem após o término da quimioterapia, exceto para algumas escalas. As escalas de imagem corporal, função sexual e funcionamento físico pioram ao longo do tratamento. A qualidade de vida mental/psicológica tem oscilações durante o tratamento, assim como a escala sobre as relações sociais. Conclusão: A qualidade de vida relacionada à saúde de mulheres com câncer de mama é afetada negativamente pelo tratamento quimioterápico, expressando maior impacto nas escalas de sintomas.


2022 ◽  
Author(s):  
LIA RAQUEL DE CARVALHO VIANA ◽  
GERLANIA RODRIGUES SALVIANO FERREIRA ◽  
STHEPHANIE DE ABREU FREITAS ◽  
KATIA NEYLA DE FREITAS MACEDO COSTA

OBJETIVO: AVALIAR A QUALIDADE DE VIDA RELACIONADA À SAÚDE DE MULHERES IDOSAS EM TRATAMENTO DE CÂNCER DE MAMA. MÉTODO: ESTUDO TRANSVERSAL, DESCRITIVO, COM ABORDAGEM QUANTITATIVA, REALIZADO COM 57 MULHERES IDOSAS EM TRATAMENTO DE CÂNCER DE MAMA. A COLETA DE DADOS OCORREU DURANTE OS MESES DE JUNHO A NOVEMBRO DE 2019, POR MEIO DE UM INSTRUMENTO SEMIESTRUTURADO PARA OBTENÇÃO DE DADOS SOCIODEMOGRÁFICOS E CLÍNICOS E OS QUESTIONÁRIOS EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE “CORE” 30 E QUALITY OF LIFE QUESTIONNAIRE – BREAST CANCER 23. OS DADOS FORAM ANALISADOS DE FORMA DESCRITIVA COM O AUXÍLIO DO STATISTICAL PACKAGE FOR THE SOCIAL SCIENCE FOR WINDOWS, VERSÃO 22.0. O PROJETO FOI APROVADO PELO COMITÊ DE ÉTICA EM PESQUISA SOB PARECER Nº 3.293.768. RESULTADOS: NA QUALIDADE DE VIDA GERAL, OBSERVOU-SE QUE AS IDOSAS APRESENTARAM BOA MÉDIA NA ESCALA DE SAÚDE GLOBAL E RAZOÁVEL NA ESCALA FUNCIONAL, DESTACANDO-SE A FUNÇÃO SOCIAL. JÁ A ESCALA DE SINTOMAS APRESENTOU MÉDIA BAIXA, DESTACANDO-SE A DIFICULDADE FINANCEIRA, INSÔNIA, FADIGA E DOR. NO QUESTIONÁRIO ESPECÍFICO, A ESCALA FUNCIONAL APRESENTOU MAIOR MÉDIA, COM DESTAQUE POSITIVO PARA A IMAGEM CORPORAL. NA ESCALA DE SINTOMAS, OS EFEITOS COLATERAIS E OS SINTOMAS DA MAMA FORAM OS QUE MAIS CONTRIBUÍRAM PARA A DETERIORAÇÃO DA QUALIDADE DE VIDA. CONCLUSÃO: A QUALIDADE DE VIDA GLOBAL APRESENTOU-SE BOA, NO ENTANTO, A MESMA SOFRE IMPACTOS DEVIDO AOS EFEITOS COLATERAIS AO TRATAMENTO.


2007 ◽  
Vol 16 (10) ◽  
pp. 950-955 ◽  
Author(s):  
Edward Wei-Chung Chang ◽  
Ying-Ying Tsai ◽  
Tsai-Wang Chang ◽  
Chao-Jung Tsao

2004 ◽  
Vol 13 (1) ◽  
pp. 155-160 ◽  
Author(s):  
Ann K. Sandgren ◽  
Amy B. Mullens ◽  
Shannon C. Erickson ◽  
Kathleen M. Romanek ◽  
Kevin D. McCaul

Author(s):  
Helen Beckmann ◽  
Christoph Heesen ◽  
Matthias Augustin ◽  
Christine Blome

Abstract Background: Treatment- and work-related aspects have been neglected in health-related quality of life (HRQOL) measures in multiple sclerosis (MS). We aimed to develop a brief instrument covering all important impairment-, activity-, participation-, and treatment-related aspects for use in research and practice. Methods: The 27-item Multiple Sclerosis Quality of Life Questionnaire (MS-QLQ27) was developed using open item collection, a multidisciplinary expert panel, and cognitive pretesting. It was evaluated for reliability, construct validity, and responsiveness with 100 patients presenting with relapse (84 at follow-up ~14 days later). Construct validity was analyzed by correlating the MS-QLQ27 with the disease-specific Hamburg Quality of Life Questionnaire in MS (HAQUAMS) and generic HRQOL instuments. The Expanded Disability Status Scale (EDSS) was used to analyze known-groups validity. Responsiveness was determined as the correlation of changes in MS-QLQ27 scores with changes in validation criteria. Results: Internal consistency was high (Cronbach α = 0.94 at baseline and 0.93 at follow-up). Convergent validity was supported by direction and magnitude of associations with disease-specific and generic instruments. Correlations with change in convergent criteria were strong, indicating responsiveness. The HAQUAMS showed the strongest associations with the MSQLQ27. The MS-QLQ27 showed the highest effect size compared with other patient-reported outcomes and the EDSS. It successfully distinguished between levels of disease severity. Conclusions: These results indicate that the MS-QLQ27 is a reliable, valid, and highly responsive instrument for assessing HRQOL during relapse evolution in MS. Its advantages are that it is brief yet comprehensive, covering work- and treatment-related aspects not addressed in previous measures.


2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 227s-227s
Author(s):  
A.C. Filankembo Kava ◽  
P. Conde ◽  
K. El Rhazi ◽  
M. Bennani ◽  
A. Benider ◽  
...  

Background: Breast cancer is the most common cancer among women. Breast cancer is ranked the first female cancer (33.4%) in Morocco; and more than 60% cases are diagnosed at stage III or IV. During the last decade, health-related quality of life (HRQOL) has become an important part of breast cancer treatment. Aim: The objective of this study is to describe self- reported HRQOL in patients with breast cancer and to investigate its associations with socio-demographic and clinical variables. Methods: A prospective study was carried out in the main oncology centers in Morocco. Quality of life was measured using the Moroccan Arabic version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C 30 (EORTC QLQ C30) and Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). Statistical data analyses were performed using descriptive statistics and multivariate analyses. Results: A total of 1463 subjects were included in the study. The subjects' mean age was 55.6 (SD. 11.2) years, 70% were married. The majority of the subjects had stage II (45.9%) and the few cases had stage IV (12.9%). Participants had a mean score for global health of 68.5. Among functional scales, social functioning scored the highest (mean 86.2, SD = 22.7). The most distressing symptom on the symptom scales was financial difficulties (mean 63.2, SD = 38.2). Using the disease-specific tool, it was found that future perspective scored the lowest (mean 40.5, SD = 37.3). On the symptom scale, arm symptoms scored the highest (mean 23.6, SD = 21.6). Significant mean differences were noted for many functional and symptom scales. Conclusion: Our results emphasize that the general HRQOL of the studied women is fairer than that of the corresponding population in other countries. This study provided baseline information on the quality of life of a large sample of Moroccan women diagnosed with breast cancer.


Sign in / Sign up

Export Citation Format

Share Document